Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine

References

• Aquilonius S. M., Hartvig P. Clinical pharmacokinetics of cholinesterase inhibitors. Clinical Pharmacokinetics 1986; 11: 236–249
   PubMed Web of Science ®Google Scholar
• Aronson J. K., Dengler H. J., Dettli L., Follath F. Standardization of symbols in clinical pharmacology. European Journal of Clinical Pharmacology 1988; 35: 1–7
   PubMed Web of Science ®Google Scholar
• Birtley R. D. N., Roberts J. B., Thomas B. H., Wilson A. Excretion and metabolism of [14C]-pyridostigmine in the rat. British Journal of Pharmacology 1966; 26: 393–402
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U., Maier U., Brinkmann A. M., Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clinical Pharmacology and Therapeutics 1985; 37: 495–501
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U., Schmezer A., Maier U., Brinkmann A., Schumm F. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis. Journal of Neurology, Neurosurgery, and Psychiatry 1990; 53: 502–506
   PubMed Web of Science ®Google Scholar
• Brinkschulte M., Breyer-Pfaff U. Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals. Naunyn-Schmiedeberg's Archives of Pharmacology 1979; 308: 1–7
   PubMedGoogle Scholar
• Chan K., Calvey T. N. Renal clearance of pyridostigmine in patients with myasthenia gravis. European Neurology 1977; 16: 69–72
   PubMedGoogle Scholar
• Daniel C., Wood F. S. Fitting Equations to Data. Wiley), (New York 1971
   Google Scholar
• Dunn M. A., Sidell F. R. Progress in medical defense against nerve agents. Journal of the American Medical Association 1989; 262: 649–652
   PubMed Web of Science ®Google Scholar
• Hammer R., Koss F. W. The pharmacokinetic profile of pirenzepine. Scandinavian Journal of Gastroenterology 1979; 14: 1–6, Suppl. 57
   PubMed Web of Science ®Google Scholar
• Havard C. W. H., Fonseca V. New treatment approaches to myasthenia gravis. Drugs 1990; 39: 1–7
   Google Scholar
• Keeler J. R., Hurst C. G., Dunn M. A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. Journal of the American Medical Association 1991; 266: 693–695
   PubMed Web of Science ®Google Scholar
• Kinsella J. L., Holohan P. D., Pessah N. I., Ross C. R. Transport of organic ions in renal cortical luminal and antiluminal membrane vesicles. Journal of Pharmacology and Experimental Therapeutics 1979; 209: 443–450
   PubMed Web of Science ®Google Scholar
• Klotz U., Kroemer H. K. The drug interaction potential of ranitidine: an update. Pharmacology and Therapeutics 1991; 50: 233–244
   PubMed Web of Science ®Google Scholar
• Kornfeld P., Samuels A. J., Wolf R. I., Osserman K. E. Metabolism of 14C-labeled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites. Neurology 1970; 20: 634–641
   PubMedGoogle Scholar
• Kornfeld P., Wolf R. I., Samuels A. J., Osserman K. E. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis. Neurology 1971; 21: 550–552
   PubMedGoogle Scholar
• Krakamp B., Tanswell P., Vogel H., Bozler G. Steady-state intravenous pharmacokinetics of pirenzepine in patients with different degrees of renal dysfunction. European Journal of Clinical Pharmacology 1989; 36: 75–78
   PubMedGoogle Scholar
• Lin J. H., Los L. E., Ulm E. H., Duggan D. E. Kinetic studies on the competition between famotidine and cimetidine in rats. Evidence of multiple renal secretory systems for organic cations. Drug Metabolism and Disposition 1988; 16: 52–56
   PubMed Web of Science ®Google Scholar
• Luke D. R., Halstenson C. E., Opsahl J. A., Matzke G. R. Validity of creatinine clearance estimates in the assessment of renal function. Clinical Pharmacology and Therapeutics 1990; 48: 503–508
   PubMedGoogle Scholar
• Maier U. Pharmakokinetik von Pyridostigmin: Untersuchungen am Menschen. PhD Thesis, University of Tübingen, Germany 1985
   Google Scholar
• Maiza A., Waldek S., Ballardie F. W., Daley-Yates P. T. Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide. Nephron 1992; 60: 12–16
   PubMedGoogle Scholar
• Muirhead M., Bochner F., Somogyi A. Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. Journal of Pharmacology and Experimental Therapeutics 1988; 244: 734–739
   PubMed Web of Science ®Google Scholar
• Osserman K. E. Myasthenia Gravis. Grune and Stratton), (London 1958
   Google Scholar
• Ott R. J., Hui A. C., Yuan G., Giacomini K. M. Organic cation transport in human renal brush-border membrane vesicles. American Journal of Physiology 1991; 261: 443–451
   Google Scholar
• Pritchard J. B., Miller D. S. Proximal tubular transport of organic anions and cations. The Kidney: Physiology and Pathophysiology2nd edn., D. W. Seldin, G. Giebisch. Raven, New York 1992; 2921–2945
   Google Scholar
• Rennick B. Renal tubule transport of organic cations. American Journal of Physiology 1981; 240F: 83–89
   Google Scholar
• Roberts C. J. C. Clinical pharmacokinetics of ranitidine. Clinical Pharmacokinetics 1984; 9: 211–221
   PubMed Web of Science ®Google Scholar
• Shim C. K., Hong J. S. Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects. Journal of Pharmaceutical Sciences 1989; 78: 990–993
   PubMed Web of Science ®Google Scholar
• Siedel J., Möllering H., Ziegenhorn J. Sensitive color reagent for the enzymic determination of creatinine. Clinical Chemistry 1984; 30: 968–969
   Web of Science ®Google Scholar
• Somogyi A. New insights into the renal secretion of drugs. Trends in Pharmacological Sciences 1987; 8: 354–357
   Google Scholar
• Somogyi A. A., Bochner F., Sallustio B. C. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clinical Pharmacology and Therapeutics 1992; 51: 379–387
   PubMed Web of Science ®Google Scholar
• Vergin H., Mascher H., Strobel K., Nitsche V. Pharmacokinetics and bioequivalence of different formulations of pirenzepine. Arzneimittel-Forschung 1986; 36: 1409–1412
   PubMed Web of Science ®Google Scholar
• Wagner J. G. Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications), (Hamilton, IL 1975
   Google Scholar